Preventing Pubertal Disruption of Glucose Regulation: Mechanisms, Risk Factors, and Clinical Strategies

Abstract

Puberty is a critical developmental period marked by significant hormonal, metabolic, and physiological changes that can transiently or persistently alter glucose regulation. Understanding the mechanisms underlying pubertal disruption of glucose homeostasis is essential for early identification and prevention of dysglycemia, particularly in populations at risk for type 1 and type 2 diabetes. This review synthesizes current epidemiological data, mechanistic insights, clinical features, diagnostic strategies, and recent advances in management, with a focus on translating evidence into practical recommendations for healthcare professionals managing pediatric and adolescent populations.

Introduction

Puberty encompasses a series of complex endocrine changes that culminate in sexual maturation and somatic growth. It is characterized by increased secretion of growth hormone (GH), insulin-like growth factor 1 (IGF-1), and sex steroids, all of which exert profound impacts on insulin sensitivity and glucose metabolism. The transient physiological insulin resistance occurring during puberty is well-documented, yet for susceptible individuals, this period may precipitate the onset or worsening of glucose dysregulation, leading to impaired glucose tolerance or diabetes. Clinicians must recognize the nuances of glucose regulation during this window to implement timely interventions and prevent long-term sequelae.

Epidemiology / Disease Burden

Recent epidemiological studies indicate that the prevalence of impaired glucose tolerance and prediabetes rises significantly during adolescence, with a global increase in youth-onset type 2 diabetes paralleling the obesity epidemic. Data from the SEARCH for Diabetes in Youth Study and other multinational cohorts highlight that pubertal insulin resistance, in combination with deteriorating β-cell function, accounts for a substantial proportion of new diabetes diagnoses in adolescents. Ethnic disparities are notable, with higher risk observed among Hispanic, African American, and Asian populations. The burden of hyperglycemia during puberty extends beyond immediate metabolic complications, increasing the risk for microvascular and macrovascular disease later in life.

Pathophysiology

The pathophysiology of pubertal glucose dysregulation is multifactorial. During mid-puberty, insulin sensitivity may decrease by up to 30%, driven by surges in GH and sex steroids, which antagonize insulin action primarily in peripheral tissues. This adaptive resistance is typically compensated by increased insulin secretion. However, in genetically or environmentally predisposed individuals, β-cell compensation may be inadequate, resulting in hyperglycemia. Moreover, adiposity, particularly visceral fat accumulation, exacerbates insulin resistance and impairs glucose uptake. Altered adipokine profiles, low-grade inflammation, and increased free fatty acid flux further deteriorate insulin signaling pathways, compounding metabolic stress during puberty.

Risk Factors

Several risk factors potentiate the disruption of glucose regulation during puberty. These include obesity, family history of diabetes, sedentary lifestyle, poor dietary patterns, polycystic ovary syndrome (PCOS), and certain ethnic backgrounds. Early onset of puberty, rapid pubertal progression, and psychosocial stressors have also been implicated. Additionally, children with pre-existing insulin resistance (e.g., those born small for gestational age or with metabolic syndrome) are at heightened risk. Recognizing these risk factors is critical for targeting preventive strategies in high-risk populations.

Clinical Features

Clinically, pubertal glucose dysregulation may present insidiously. Symptoms of hyperglycemia—polyuria, polydipsia, unexplained weight loss—may be subtle or absent. Instead, clinicians should be vigilant for signs such as acanthosis nigricans, central adiposity, and rapid BMI increase. In adolescents with type 1 diabetes, puberty is often associated with increased insulin requirements and greater glycemic variability. For those with type 2 diabetes, progression from impaired glucose tolerance to overt diabetes may accelerate during this period. Early identification of at-risk individuals through clinical features and risk stratification is paramount.

Diagnosis

Diagnosis of pubertal glucose dysregulation relies on a combination of clinical assessment and laboratory evaluation. Fasting plasma glucose, oral glucose tolerance test (OGTT), and glycated hemoglobin (HbA1c) remain the cornerstone diagnostic tools. Recent evidence supports the use of continuous glucose monitoring (CGM) in high-risk adolescents for early detection of glycemic excursions. Screening should be individualized based on risk profile, and repeat assessments may be warranted during pubertal transition, particularly in overweight or obese youth, those with a family history of diabetes, or those with clinical markers of insulin resistance.

Treatment & Management

Management strategies for preventing and mitigating pubertal glucose dysregulation center on lifestyle modification, including dietary counseling, increased physical activity, and behavioral interventions. These are particularly effective when initiated before or at the onset of puberty. Pharmacologic therapy, such as metformin, may be considered in adolescents with significant insulin resistance or impaired glucose tolerance unresponsive to lifestyle measures, as endorsed by major guidelines. In those with established diabetes, individualized insulin regimens and regular monitoring are essential to accommodate pubertal hormonal fluctuations. Multidisciplinary care, involving endocrinologists, dietitians, psychologists, and community support, optimizes outcomes.

Recent Advances / Emerging Therapies

Recent advances in understanding the molecular underpinnings of pubertal insulin resistance have led to exploration of novel therapeutic targets, including modulation of gut microbiota, anti-inflammatory agents, and incretin-based therapies. Randomized controlled trials are evaluating the efficacy of GLP-1 receptor agonists and SGLT2 inhibitors in adolescent populations with impaired glucose tolerance, with promising preliminary results. Additionally, digital health interventions, such as mobile health applications and telemedicine, enhance engagement and monitoring in at-risk youth. These innovations offer hope for more tailored and effective preventive strategies.

Guideline Recommendations

Current guidelines from the American Diabetes Association, International Society for Pediatric and Adolescent Diabetes, and Endocrine Society emphasize early identification, risk-based screening, and lifestyle modification as the cornerstone of prevention during puberty. Pharmacologic intervention is recommended for select high-risk individuals. Guidelines also underscore the importance of family-centered care, psychosocial support, and regular follow-up throughout adolescence. Ongoing research and guideline updates are needed as new evidence emerges regarding optimal preventive and therapeutic strategies.

Conclusion

Preventing pubertal disruption of glucose regulation requires a multifaceted approach grounded in early risk identification, mechanistic understanding, and evidence-based intervention. Given the increasing prevalence of dysglycemia in adolescents, proactive measures—including lifestyle optimization, targeted screening, and emerging therapies—are crucial for reducing the lifetime burden of diabetes and its complications. Continued research and collaborative care models will be vital to advance prevention and improve outcomes for at-risk youth during this vulnerable developmental window.